Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) Operating Expenses (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Operating Expenses for 6 consecutive years, with $71.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 79.67% to $71.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $222.8 million, a 49.1% increase, with the full-year FY2025 number at $222.8 million, up 48.33% from a year prior.
  • Operating Expenses was $71.4 million for Q4 2025 at GeneDx Holdings, up from $64.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $155.2 million in Q1 2021 to a low of $24.8 million in Q2 2021.
  • A 5-year average of $59.7 million and a median of $52.7 million in 2021 define the central range for Operating Expenses.
  • Biggest YoY gain for Operating Expenses was 296.8% in 2022; the steepest drop was 56.17% in 2022.
  • GeneDx Holdings' Operating Expenses stood at $80.2 million in 2021, then fell by 2.93% to $77.9 million in 2022, then tumbled by 43.3% to $44.1 million in 2023, then dropped by 10.01% to $39.7 million in 2024, then surged by 79.67% to $71.4 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Operating Expenses are $71.4 million (Q4 2025), $64.3 million (Q3 2025), and $42.5 million (Q2 2025).